Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

501 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.
Spratt DE, Dai DLY, Den RB, Troncoso P, Yousefi K, Ross AE, Schaeffer EM, Haddad Z, Davicioni E, Mehra R, Morgan TM, Rayford W, Abdollah F, Trabulsi E, Achim M, Tapia ELN, Guerrero M, Karnes RJ, Dicker AP, Hurwitz MA, Nguyen PL, Feng FFY, Freedland SJ, Davis JW. Spratt DE, et al. Eur Urol. 2018 Jul;74(1):107-114. doi: 10.1016/j.eururo.2017.11.024. Epub 2017 Dec 10. Eur Urol. 2018. PMID: 29233664 Free PMC article.
Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity.
Ghadjar P, Jackson A, Spratt DE, Oh JH, Munck af Rosenschöld P, Kollmeier M, Yorke E, Hunt M, Deasy JO, Zelefsky MJ. Ghadjar P, et al. Among authors: spratt de. Eur Urol. 2013 Dec;64(6):931-8. doi: 10.1016/j.eururo.2013.02.001. Epub 2013 Feb 14. Eur Urol. 2013. PMID: 23522772 Free PMC article.
A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy.
Osborne JR, Green DA, Spratt DE, Lyashchenko S, Fareedy SB, Robinson BD, Beattie BJ, Jain M, Lewis JS, Christos P, Larson SM, Bander NH, Scherr DS. Osborne JR, et al. Among authors: spratt de. J Urol. 2014 May;191(5):1439-45. doi: 10.1016/j.juro.2013.10.041. Epub 2013 Oct 14. J Urol. 2014. PMID: 24135437 Free PMC article.
The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy.
Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Polkinghorn W, McBride S, Kollmeier M, Yamada Y, Zelefsky MJ. Zumsteg ZS, et al. Among authors: spratt de. Eur Urol. 2015 Jun;67(6):1009-1016. doi: 10.1016/j.eururo.2014.09.028. Epub 2014 Oct 11. Eur Urol. 2015. PMID: 25308970 Free PMC article.
Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR, Zhao SG, Chang SL, Tomlins SA, Erho N, Sboner A, Schiewer MJ, Spratt DE, Kothari V, Klein EA, Den RB, Dicker AP, Karnes RJ, Yu X, Nguyen PL, Rubin MA, de Bono J, Knudsen KE, Davicioni E, Feng FY. Evans JR, et al. Among authors: spratt de, de bono j. JAMA Oncol. 2016 Apr;2(4):471-80. doi: 10.1001/jamaoncol.2015.4955. JAMA Oncol. 2016. PMID: 26746117 Free PMC article.
Independent surgical validation of the new prostate cancer grade-grouping system.
Spratt DE, Cole AI, Palapattu GS, Weizer AZ, Jackson WC, Montgomery JS, Dess RT, Zhao SG, Lee JY, Wu A, Kunju LP, Talmich E, Miller DC, Hollenbeck BK, Tomlins SA, Feng FY, Mehra R, Morgan TM. Spratt DE, et al. BJU Int. 2016 Nov;118(5):763-769. doi: 10.1111/bju.13488. Epub 2016 Apr 19. BJU Int. 2016. PMID: 27009882 Free article.
501 results